K. Possinger
- Oncology top 1%
- Cancer Treatment and Pharmacology 46
- HER2/EGFR in Cancer Research 25
- Colorectal Cancer Treatments and Studies 13
- Cancer Research top 2%
- Breast Cancer Treatment Studies 29
- Cancer Genomics and Diagnostics 8
- Biomaterials top 5%
- Hematology top 5%
- Genetics top 5%
- Estrogen and related hormone effects 13
-
- Advanced Breast Cancer Therapies 21
-
- Monoclonal and Polyclonal Antibodies Research 9
- Co-authors
- Orhan SezerJan EuckerDiana LüftnerMartin FennerPeter SchmidHelen KerrJackie WallingAdrian L. Harris
- Cited by
- OncologyCancer ResearchBiomaterials
- Journals
- Journal of Clinical Oncology (20 papers)European Journal of Cancer (13 papers)Annals of Oncology (10 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
K. Possinger
146 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 1.9k
- Cancer Research 798
- Biomaterials 390
- Hematology 289
- Genetics 231
Countries citing papers authored by K. Possinger
This map shows the geographic impact of K. Possinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Possinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Possinger more than expected).
Fields of papers citing papers by K. Possinger
This network shows the impact of papers produced by K. Possinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Possinger. The network helps show where K. Possinger may publish in the future.
Co-authorship network
The 25 scholars most cited alongside K. Possinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 41 | |
| 2 | ACT-FASTER: An epidemiological prospective Cohort Study to describe treatment patterns of fulvestrant and exemestane in postmenopausal patients with advanced HR+ breast cancer under real-life conditions in Germany | 2011 | 0 |
| 3 | 2011 | 1 | |
| 4 | 2009 | 22 | |
| 5 | 2008 | 40 | |
| 6 | 2004 | 0 | |
| 7 | 2002 | 0 | |
| 8 | Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results | 2001 | 6 |
| 9 | 2001 | 36 | |
| 10 | 2001 | 65 | |
| 11 | 2000 | 18 | |
| 12 | 2000 | 9 | |
| 13 | 2000 | 16 | |
| 14 | 2000 | 3 | |
| 15 | 2000 | 31 | |
| 16 | 2000 | 18 | |
| 17 | 1999 | 33 | |
| 18 | 1998 | 3 | |
| 19 | 1998 | 181 | |
| 20 | 1993 | 10 |
About K. Possinger
K. Possinger is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Hematology and Pathology and Forensic Medicine, having authored 156 papers that have together received 3.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (46 papers), Breast Cancer Treatment Studies (29 papers), HER2/EGFR in Cancer Research (25 papers), Advanced Breast Cancer Therapies (21 papers), Colorectal Cancer Treatments and Studies (13 papers), Estrogen and related hormone effects (13 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Cancer Genomics and Diagnostics (8 papers). The work is most often cited by research in Oncology (1.9k citations), Cancer Research (798 citations), Biomaterials (390 citations), Hematology (289 citations) and Genetics (231 citations). K. Possinger has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Orhan Sezer, Jan Eucker, Diana Lüftner, Martin Fenner, Peter Schmid, Helen Kerr, Jackie Walling, Adrian L. Harris, J Carmichael and Maria K. Beykirch. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Annals of Hematology and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.